Figure 2
Recruitment of HA-specific effector T cells in the draining lymph node of Treg-depleted AB1-HA bearing BALB/c mice. (a) Six-week-old BALB/c (n=8, black line, circle) or 2-month-old InsHA (n=7, gray line, square) mice were depleted of Tregs by a single injection of 125 μg PC61 at day −1 and subsequently injected s.c. with 5 × 105 AB1-HA or AB1 tumor cells at day 0. Graph shows the Kaplan–Meyer survival curves of mice in the absence of Tregs. The survival of BALB/c mice was statistically different from the survival of InsHA mice (**P=0.0017, with a log-rank (Mantel–Cox) test). (b) InsHA mice (n=4) of 6 weeks of age received 5 × 105 AB1-HA tumors s.c. Age-matched BALB/c mice (n=4) were injected s.c. with 5 × 105 AB1-HA or AB1 tumor cells at day 0. The mice injected with AB1-HA were separated into two groups and treated or not with a single injection of 125 μg PC61 at day −1 for Treg depletion. + or − refers to PC61 treatment or not, respectively. Normal BALB/c LN and InsHA pancreatic LN mice were used as negative and positive controls, respectively. At day 15, mice were killed and the tumor draining lymph nodes were harvested. mRNA was extracted, cDNA was synthesized and a TCR-HA TS-Q-PCR was performed. Graph shows the relative quantity of TCR-HA+ cells in each lymphoid organs at day 15. Data are representative of three experiments using two tumor lines AB1-HA and 4T1-HA.
